Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

(Updated - January 25, 2018 6:33 AM EST)

Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.

GUIDANCE:

Biogen sees FY2018 EPS of $24.20-$25.20 consensus of $24.16 and revenue of $12.7-13 billion, versus the consensus of $12.68 billion.

• Revenue is expected to be approximately $12.7 billion to $13.0 billion.
• GAAP and non-GAAP R&D expense is expected to be approximately 16% to 17% of total revenue.
• This guidance does not include any impact from potential acquisitions or large business development transactions, as both are hard to predict.
• GAAP and non-GAAP SG&A expense is expected to be approximately 15% to 16% of total revenue.
• GAAP tax rate is expected to be approximately 23.5% to 24.5%; non-GAAP tax rate is expected to be approximately 22.5% to 23.5%.
• GAAP diluted EPS is expected to be between $22.20 and $23.20.
• Non-GAAP diluted EPS is expected to be between $24.20 and $25.20.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• AeroVironment restates quarterly financials, citing $89M goodwill error